Part of the appeal of amylin analogs is the potential to drive weight loss without causing the same level of tolerability problems as GLP-1 receptor agonists. Lilly reported relatively low rates of ...

The phase 1b trial’s primary endpoints are the occurrence of adverse events, including dose-limiting toxicities, and the ...

Once hailed as the future of immuno-oncology, it’s been a tough few months for any remaining fans of anti-TIGIT antibodies. | ...

Spain’s SpliceBio will use $135 million from a series B round backed by Sanofi and Roche to advance its lead gene editing ...

CSPC will use its artificial-intelligence-driven, dual-engine efficient drug discovery platform to analyze the binding ...

Bristol Myers Squibb didn’t want to choose between clinical expertise and financial know-how when selecting a new leader. | ...

Merck KGaA has shed more light on the failure of its lupus drug in one cohort of patients, while pointing to secondary ...

BioNTech is buying fellow German mRNA vaccine developer CureVac in an all-stock transaction that values the acquired biotech ...

Atraverse Medical has raised $29.4 million to fund its minimally invasive system for accessing the inner chambers of the ...

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

The offer is the result of a memorandum of understanding signed by both Astellas and Japanese think tank Mitsubishi Research ...

Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and ...